Table 2 Clinical characteristics of the IgAN patients according to disease progression
From: Urinary sediment mRNA as a potent biomarker of IgA nephropathy
|  | Progression (n = 26) | Non-progression (n = 174) | P |
|---|---|---|---|
Age (years) | 51.31 ± 19.08 | 41.05 ± 15.06 | 0.014 |
Male (n, %) | 18 (69.2%) | 81 (46.6%) | 0.025 |
BMI (kg/m2) | 24.51 ± 3.17 | 23.81 ± 3.46 | 0.347 |
HTN (n, %) | 20 (76.9%) | 53 (30.5%) | < 0.001 |
DM (n, %) | 1 (3.8%) | 11 (6.3%) | 0.502 |
Albumin (g/dL) | 3.52 ± 0.63 | 3.96 ± 0.50 | < 0.001 |
IgA (mg/dL) | 282.69 ± 87.78 | 308.48 ± 95.82 | 0.198 |
eGFR (ml/min/1.73 m2) | 33.25 ± 15.64 | 87.54 ± 34.26 | < 0.001 |
Urine PCR (g/gCr) | 3.72 ± 2.97 | 1.33 ± 1.67 | < 0.001 |
Use of ARB or ACEi before renal biopsy (n, %) | 9 (34.6%) | 49 (28.2%) | 0.499 |
Use of ARB or ACEi after renal biopsy (n, %) | 22 (84.6%) | 123 (70.7%) | 0.103 |
Use of immunosuppressant after renal biopsy (n, %) | 23 (88.5%) | 105 (60.3%) | 0.003 |
Urine RBC grade (n, %) | Â | Â | 0.054 |
 < 5/HPF | 7 (25.9%) | 38 (21.8%) |  |
 5–9/HPF | 4 (14.8%) | 24 (13.8%) |  |
 10–29/HPF | 11 (40.7%) | 36 (20.7%) |  |
 ≥ 30/HPF | 5 (18.5%) | 76 (37.8%) |  |
Oxford classification M | Â | Â | 0.001 |
 0 | 6 (23.1%) | 103 (59.2%) |  |
 1 | 20 (76.9%) | 70 (40.8%) |  |
Oxford classification E | Â | Â | 0.238 |
 0 | 17 (65.4%) | 129 (74.1%) |  |
 1 | 9 (34.6%) | 45 (25.9%) |  |
Oxford classification S | Â | Â | 0.367 |
 0 | 17 (65.4%) | 123 (70.7%) |  |
 1 | 9 (34.6%) | 51 (29.3%) |  |
Oxford classification T |  |  | < 0.001 |
 0 | 14 (53.8%) | 158 (90.8%) |  |
 1 | 12 (46.2%) | 16 (9.2%) |  |
Oxford classification C | Â | Â | 0.006 |
 0 | 14 (53.8%) | 139 (79.9%) |  |
 1 | 12 (46.2%) | 35 (20.1%) |  |